Coordinating Global Capabilities To Support A Gene Therapy Targeting A Rare Neurodegenerative Disorder

A pioneering biotech company sought an experienced partner to support its early-stage development of a gene therapy targeting a rare neurodegenerative disease. With the goal of advancing toward clinical trials, the company needed expertise in both preclinical safety assessment and Chemistry, Manufacturing, and Controls (CMC) services.

Labcorp’s multidisciplinary teams collaborated seamlessly to provide comprehensive support, including Good Laboratory Practice (GLP) toxicology and biodistribution studies, ensuring regulatory compliance and robust safety data. Additionally, Labcorp’s CMC services played a crucial role in optimizing the manufacturing process to meet regulatory standards. Learn how this partnership helped the biotech successfully achieve Investigational New Drug (IND) approval, accelerating progress toward potential treatment for patients in need.